Americans have weeks left to claim $5,000 from $1 million payout — are you eligible for extra cash?
Americans eligible $5,000 data breach settlement warning: A $1.09-million payout is waiting for anyone hit by the Community Care Alliance hack, and the clock is ticking. Victims can claim up to $5,000 for fraud costs or choose two-year credit-monitoring coverage, but forms must reach settlement administrators by October 1, 2025. Submit online at the official CCADataSettlement.com portal, attach proof of expenses, and pick check, PayPal, or Venmo payment. No fee, no lawyer needed—just act fast to secure your share and lock down your identity before crooks do more damage.
If you were impacted by the Community Care Alliance data breach in July 2024, you may be entitled to significant compensation—up to $5,000 in cash or two years of premium credit and identity protection services. Following a massive ransomware attack that exposed the sensitive health and personal data of nearly 115,000 individuals, Community Care Alliance has agreed to a $1.09 million class action settlement. But time is running out. The deadline to file your claim is October 1, 2025. Whether you experienced fraud or simply want to protect your identity. In a major win for data privacy victims, Community Care Alliance has agreed to a $1.09 million class action settlement after a massive data breach compromised the personal and health information of nearly 115,000 Americans. If you were affected, you could now claim up to $5,000 in reimbursement or two years of free credit monitoring—but you must act fast before the October 1, 2025 deadline. In early July 2024, cybercriminals from the notorious Rhysida ransomware group hacked into the servers of Community Care Alliance, a behavioral health organization based in Rhode Island. The attackers stole 2.5 terabytes of data, including:
Full names
Social Security numbers
Dates of birth
Medical diagnoses and treatment info
Health insurance details
Driver's license and government ID numbers The breach impacted over 114,975 individuals and led to serious concerns about identity theft and medical fraud. Victims were left vulnerable to scams, unauthorized charges, and long-term data misuse. You're eligible to file a claim if your information was exposed in the Community Care Alliance data breach between July 1 and July 5, 2024. Even if you haven't received a breach notification letter yet, you may still qualify. The settlement applies to anyone whose protected health information (PHI) or personal identifying information (PII) was compromised during the breach. Under the terms of the $1.09 million class action settlement, affected individuals may receive:
Up to $5,000 in reimbursement for documented out-of-pocket losses (such as fraud-related charges, credit monitoring services, or time spent resolving identity theft)
in reimbursement for documented out-of-pocket losses (such as fraud-related charges, credit monitoring services, or time spent resolving identity theft) A pro-rata cash payment , currently estimated to be around $100 , depending on the number of valid claims submitted
, currently estimated to be around , depending on the number of valid claims submitted Two years of free three-bureau credit monitoring, dark web monitoring, $1 million in identity theft insurance, and full identity restoration services No proof of identity theft is required for the basic cash claim or the free monitoring option. To claim your benefits, visit the official settlement website: www.ccadatasettlement.com You can file your claim online or download a PDF to mail it. Here's what you'll need:
Your name and contact information Your unique notice ID (if you received one) Any documentation showing proof of expenses for reimbursement claims Your preferred payment method (check, PayPal, Venmo, etc.) Make sure to keep copies of everything you submit. Action Deadline File your claim October 1, 2025 Opt out or object to the terms September 2, 2025 Final court approval hearing October 8, 2025 If you don't file a claim, you won't get any compensation. If you do nothing, you will still be bound by the settlement and lose the right to sue individually. If you're requesting reimbursement (up to $5,000), you'll need to submit documents such as: Credit card or bank statements showing unauthorized charges
Receipts for credit monitoring or identity theft services
Bank fees, late charges, or overdraft fees
Pay stubs or other documentation for time lost from work
Police or fraud reports (if available) All expenses must have been incurred on or after July 29, 2024. Once the final approval is granted by the court after the October 8 hearing, the settlement administrator will begin issuing payments and providing credit monitoring codes. Most valid claims are expected to be processed within 30–60 days after final approval—though it may take longer if there are appeals.
You can choose between receiving a check, PayPal, Venmo, or other electronic payment options, depending on what's offered during the filing process. Only file your claim through the official settlement website ending in .com or pnclassaction.com. You should never be asked to pay a fee or provide unnecessary sensitive information. Legitimate class action claims do not cost anything to file.
Stay safe by:
Avoiding suspicious emails asking for banking info
Double-checking the domain before entering personal details
Calling the toll-free helpline listed on the official site if unsure This is one of the most serious healthcare data breaches of 2024, exposing thousands to long-term risks. The settlement not only compensates victims but also sends a clear message to healthcare providers to invest in better data protection. If your Social Security number, medical history, or insurance information may have been exposed, you have a right to claim compensation or protection. If you were impacted by the Community Care Alliance data breach, don't wait. File your claim by October 1, 2025, to receive the cash reimbursement or credit monitoring benefits. Even if you don't have documents for expenses, you can still receive free identity protection—and that alone can save you thousands in the long run.
How do I file a Community Care Alliance data breach settlement claim? Complete the online form at CCADataSettlement.com and upload any expense proof before October 1, 2025.
What is the deadline for the $5,000 Community Care Alliance settlement? All claims, opt-outs, or objections must be submitted by October 1, 2025.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
3 hours ago
- Mint
NIH Grant Cuts Arent Saving Money. Theyre Wasting It.
(Bloomberg Opinion) -- The Trump administration's waves of massive cuts to funding at the National Institutes of Health are framed as a recasting of research priorities and a way to save taxpayer money. Another way to frame it is an exercise in massive waste. In terminating nearly 750 NIH grants over the past two months, the government dumped years of investment down the drain. The unceremonious end to those projects means we won't know the answers to studies that intended to improve the health of Americans. According to a Bloomberg Opinion analysis(1), Health and Human Services data show that some $373 million had already been spent on the 242 discontinued R01 grants, an NIH award that is considered critical to launching a successful career. Researchers tend to get that chunk of funding — typically a sizable amount that supports their work for 3 to 5 years — after they've done a few years of preliminary work. It's all geared toward asking a big scientific question. Our analysis doesn't include the untold number of NIH grants at Harvard University affected by the administration's $2.2 billion federal funding freeze this week — a punishment for refusing to comply with the government's long list of demands. But even if those funds are eventually restored, the disruption risks derailing studies related to ALS, tuberculosis and many other health conditions. Funding was pulled just as some of these projects were getting off the ground, while others were rounding into their last year of funding — a point where enough data would finally be collected to offer concrete results. Our analysis found that nearly 40% of the canceled R01 grants supported research that had yet to produce findings, meaning all of the agency's prior investments won't benefit the public. Take, for example, the abrupt end to Washington University of St. Louis professor Jeremy Goldbach's five-year grant to test the first evidence-backed intervention intended to help teachers, administrators and social workers support LGBTQ youth. A little over three years in, Goldbach had collected a massive amount of data from 20 schools — thousands of students had participated. But without his last rounds of funding, he won't be able to track the program's efficacy at the last four schools needed for the results to be statistically meaningful. That's more than $2.1 million that NIH already spent on the project down the drain, all because the government pulled the last few hundred thousand. (Goldbach's grant was one of many caught up in a sweep of cuts related to President Trump's gender ideology executive order.) But the loss goes beyond that. Goldbach's project built off years of earlier work. Before getting to the point where a review panel of more than two dozen experts felt the concept was promising enough to merit a large-scale study, the researcher had to design and test it. That work was supported by two earlier awards from NIH and financial help from foundations, which together amounted to nearly $900,000 in investment in the project. Moreover, about 15 people's jobs are on the line between the loss of this funding and around seven other terminated grants for studies that Goldbach is a collaborator on. At the other end of the spectrum, Northwestern University professor Michelle Birkett's $3.8 million grant was ended in the first of its five years. The funding was awarded to understand —and ultimately address — disparities in HIV transmission and substance use among gay men and transgender women. Although only a fraction of that promised money had been spent, Birkett had invested years of work into designing and securing funding for the study and had already recruited a community board across each of the five cities where it was poised to launch. Countless stories of similarly needless waste — research interrupted midstream and sidelined careers— live behind the HHS's long list of canceled funding. That translates into a massive number of health insights the public simply won't know about — yet had already paid to support. So many of those unanswered questions centered on prevention: How can we encourage simple changes that could have a big impact on the physical and mental health of Americans — and ultimately save the health care system money? For example, a cluster of projects devoted to improving uptake of the HPV vaccine, which has stalled in recent years, was among the research that recently lost funding. Not enough adolescents are getting the shots despite a growing body of data showing its ability to prevent deaths from cervical cancer in women and potentially lower the rates of head and neck, anal, penile, vaginal and vulvar cancers. Some of those HPV vaccine studies were well underway but, as with Goldbach's project, had yet to enroll enough volunteers to yield meaningful data on how to convince people to get the shot. Ultimately, that doesn't just waste the taxpayer money already spent on those grants; it could also cost the health care system later, in the form of otherwise preventable cancer cases. Abandoning these projects is far from an exercise in efficiency, as the Trump administration likes to tout. A more accurate word to sum up what's happening with these cuts would be: nonsensical. More From Bloomberg Opinion: Want more Bloomberg Opinion? OPIN GO. Or subscribe to our daily newsletter. (1) Bloomberg Opinion analyzed 748 terminated NIH grants from the HHS TAGGS data as of April 16. We merged in additional information about each grant, including the project start date and the number of associated publications, from the NIH RePORTER database. The length of each study is the time between the project's beginning and the grant termination date, which we visualize for three of the most common award types: R01, U01 and U54 grants. The funding already spent on R01s is calculated from the 'total amount expended' field in the HHS data. This column reflects the personal views of the author and does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners. Lisa Jarvis is a Bloomberg Opinion columnist covering biotech, health care and the pharmaceutical industry. Previously, she was executive editor of Chemical & Engineering News. Carolyn Silverman is a data journalist for Bloomberg Opinion. She previously served as a data scientist for the University of Chicago Crime Lab and Education Lab. More stories like this are available on
Hindustan Times
10 hours ago
- Hindustan Times
The Political Race for Fewer Cures
America is leading the world into a new era of medical cures and biologic treatments, and the benefits to human health promise to be staggering. Yet why is America's political class—first Democrats and now Republicans—working hard to delay and maybe forestall this progress? Democrats have done much harm already with their Inflation Reduction Act price controls, as research and venture funding have declined. Now comes President Trump, who last week threatened drug companies with price controls or worse if they don't cut prices as he wants. Mr. Trump's excuse is that other countries are 'free riding' on American innovation. His solution: Demand manufacturers give Americans their 'most-favored nation' (MFN) price—i.e., the lowest in other developed countries like Canada and the U.K. If drug makers refuse, he may yank their drug approvals, harass them with lawsuits and more. 'If you refuse to step up, we will deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices,' Mr. Trump wrote to 17 large drug makers on Thursday. *** It's true that countries with government-run health systems like Canada, the U.K. and France pay less for drugs than Medicare and U.S. private insurers do. But the price disparities Mr. Trump cites don't include all the discounts that U.S. manufacturers provide insurers, hospitals, pharmacies and the feds. A Berkeley Research Group study last year found that drug makers received about 50% on a dollar of revenue for every drug they sold in the U.S. The rest was paid out in fees and discounts to intermediaries and the government. Some discounts are passed onto Americans through lower insurance premiums, though some boost hospital and insurer profits. Medicare and Medicaid spent $181 billion on prescription drugs in 2023 versus $662 billion for hospitals. Patient out-of-pocket spending on prescription drugs accounts for about 1% of U.S. healthcare spending. Drugs aren't the main driver of healthcare premiums, patient costs or government spending. Manufacturers benefit for a few years from patent protection after medicines launch, but then they face stiff competition from follow-on medicines and generics. Prices typically fall by more than half after patent protection ends. Sales of AbbVie's auto-immune blockbuster Humira have shrunk by more than half since its patent monopoly ended in 2023. Unbranded generics in the U.S. make up 90% of all prescriptions and cost one-third less than in other economically developed countries, according to RAND. Generics also make up a much larger share of prescriptions in the U.S. than in other countries. That's because higher manufacturer list prices provide an incentive to develop biosimilars and generics. This market competition can reduce prices more than government price controls while providing an incentive for drug makers to continue to innovate. Mr. Trump's order would do the opposite by discouraging development of generics and new breakthrough treatments. Mr. Trump claimed last week that drug manufacturers receive 'generous research subsidies.' Not true. Universities do, and some of their research can lead to future drugs. But the pharmaceutical industry spent $141 billion on research and development in 2022, nearly 40 times as much as the National Institutes of Health did on research directly related to drug development. Browbeating companies, as Mr. Trump is doing, could spur them to move more intellectual property to China, where Xi Jinping is rolling out the red carpet. And it will likely result in fewer new drugs developed and sold in the U.S., especially in riskier research fields like neurologic and rare genetic diseases. If drug makers refuse Mr. Trump's MFN price, he has directed his Attorney General and Federal Trade Commission to take antitrust 'enforcement action.' Mr. Trump also ordered his Food and Drug Administration Commissioner Marty Makary to modify or revoke approvals 'for those drugs that maybe be unsafe, ineffective, or improperly marketed.' Translation: Nice medicine you have there. Terrible if something happened to it. *** It's not clear what legal authority Mr. Trump plans to invoke to do any of this, and it would presumably need a rule-making that could be challenged in court. His plan appears to usurp Congress's power over commerce and violate the Supreme Court's major questions doctrine. It may also violate due process and property and contractual rights. Mr. Trump had a chance to include drug prices in his trade negotiations with other countries. But he failed to do so with Europe and Japan. Instead he is now going to import foreign price controls to punish U.S. companies—and the Americans who will get fewer cures as a result.
NDTV
10 hours ago
- NDTV
China Reports More Than 7000 Chikungunya Cases: Symptoms, Risk Factors, Complications And More
More than 7000 cases of chikungunya have been reported in China. Guangdong province in China is the worst-hit area, reporting the maximum number of cases. The US Centres for Disease Control and Prevention (CDC) has issued a Level 2 (Practice Enhanced Precautions) travel alert for all Americans travelling to China. The CDC has also recommended vaccination for travellers visiting an area with a chikungunya outbreak. For the unversed, chikungunya is a viral vector-borne disease. It is transmitted to humans through the bite of infected mosquitoes, primarily the Aedes aegypti and Aedes albopictus species. The virus doesn't spread from person to person through close contact, however, blood transmission may be possible. What are the symptoms of chikungunya? Chikungunya is characterised by a sudden onset of fever and severe joint pain. The incubation period is typically 3-7 days. High fever Severe joint pain and swelling Muscle pain Headache Fatigue Rash Severe joint pain is one of the distinct symptoms of chikungunya, which may last for weeks, months and even years. Older adults or those with pre-existing conditions are also likely to experience severe joint pain, especially during extreme weather conditions. Other symptoms are generally self-limiting and improve within a week. What are the treatment options for chikungunya? Chikungunya treatment mainly focuses on relieving symptoms. Anti-inflammatory medicines and pain killers are usually used to manage fever and joint and muscle pain. Rest and adequate hydration also assist in quick recovery. Is chikungunya fatal? Chikungunya is rarely fatal. However, the elderly, newborns or individuals with pre-existing health conditions remain at a higher risk of severe complications. Most symptoms are generally self-limiting and last for 2-3 days. The disease is characterised by an abrupt onset of fever, which is frequently accompanied by joint pain. Other common signs and symptoms include muscle pain, headache, nausea, fatigue and rash. How to prevent chikungunya Chikungunya prevention involves reducing mosquito exposure and controlling mosquito populations. Effective strategies include: Use insect repellent containing DEET or eucalyptus oil, especially when outdoors Wear long-sleeved clothes and full-length pants to minimise skin exposure Use mosquito nets while sleeping, especially in areas where chikungunya is prevalent Eliminate standing water, as this is where mosquitoes breed Install screens on windows and doors to keep mosquitoes out Stay indoors during peak hours when mosquitoes that transmit chikungunya are most active, especially at dawn and dusk. According to the World Health Organisation, the chikungunya virus was first identified in the United Republic of Tanzania in 1952 and subsequently in other countries in Africa and Asia. Urban outbreaks were first recorded in Thailand in 1967 and in India in the 1970s. Currently, there are two chikungunya vaccines available in the United States: IXCHIQ (a live-attenuated vaccine and VIMKUNYA (a virus-like particle vaccine).
